ReviewBiomedical reports2018
Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker?
Review in Biomedical reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A systematic review of natural products targeting Nrf2-Keap1-ARE pathway and their influence on neurodegenerative disorders.Inflammopharmacology · 2025Pooled it
- A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.BMC cancer · 2023Trial
- EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.Nature communications · 2026Article
- Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer.Cancer research · 2025Article
- Neuron-Glia Crosstalk in the Regulation of Astrocytic Antioxidative Mechanisms Following CNS Injury.Antioxidants (Basel, Switzerland) · 2025Review
- Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component.Frontiers in oncology · 2025Article
- Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma.Oncology letters · 2025Article
- Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance.Cancer metastasis reviews · 2024Review
- Prevalence and Associations of Co-occurrence ofGlobal medical genetics · 2024Article
- TRIM13 inhibits cell proliferation and induces autophagy in lung adenocarcinoma by regulating KEAP1/NRF2 pathway.Cell cycle (Georgetown, Tex.) · 2023Article
- Flavored E-cigarette product aerosols induce transformation of human bronchial epithelial cells.Lung cancer (Amsterdam, Netherlands) · 2023Article
- Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.Frontiers in immunology · 2023Review
- Black tea bioactive phytoconstituents realign NRF2 for anticancer activity in lung adenocarcinoma.Frontiers in pharmacology · 2023Article
- APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.Lung cancer (Amsterdam, Netherlands) · 2022Article
- Exosomes fromCancers · 2022Article
- Targeting lncRNAs in programmed cell death as a therapeutic strategy for non-small cell lung cancer.Cell death discovery · 2022Review
- Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them.International journal of molecular sciences · 2021Review
- Role of NRF2 in Lung Cancer.Cells · 2021Review
- The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.Oncotarget · 2021Article
- CircKEAP1 Suppresses the Progression of Lung AdenocarcinomaFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, lung cancer remains the most common cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 85% of all diagnosed lung cancer cases. Chemotherapy is considered the standard of care for patients with advanced NSCLC; however, the tumors can develop mechanisms that inactivate these drugs. Comparative genomic analyses have revealed that disruptions in the kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2-related factor-2 (Nrf2) pathway are frequent in NSCLC, although Nrf2 mutations occur less frequently than Keap1 mutations. As the Keap1-Nrf2 pathway appears to be a primary regulator of key cellular processes that aid to resist the action of chemotherapy drugs, the clinical implementation of Nrf2 inhibitors in patients with advanced NSCLC may be a useful therapeutic approach for patients harboring KEAP1-NRF2 mutations. The aim of the present review was to highlight findings of how constitutive Nrf2 activation may be a specific biomarker for predicting patients most likely to benefit from classical chemotherapy drugs, overall improving patient survival rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.